Almanac 2011: Heart failure. The national society journals present selected research that has driven recent advances in clinical cardiology

Heart

Volumn 97, Issue 20, 2011, Pages 1643-1649

  Clark, Andrew L ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FUROSEMIDE; IRON; IVABRADINE; LISINOPRIL; LOSARTAN; NESIRITIDE; PLACEBO; POTASSIUM DERIVATIVE; RLY 5016; ROLOFYLLINE; SPIRONOLACTONE; TRIMETAZIDINE; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGY; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; DRUG MEGADOSE; EXERCISE; HEALTH CARE ORGANIZATION; HEALTH CARE PRACTICE; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERKALEMIA; IRON DEFICIENCY; MEDICAL AUDIT; MEDICAL LITERATURE; MEDICAL RESEARCH; NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE; OUTCOME ASSESSMENT; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TELEMONITORING;

BIOMEDICAL RESEARCH; CARDIOLOGY; ENGLAND; HEART FAILURE; HUMANS; PERIODICALS AS TOPIC; SOCIETIES, MEDICAL; WALES;

EID: 80053214360     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300897     Document Type: Review

References (76)

1. Cleland JG, McDonagh T, Rigby AS, et al. National Heart Failure Audit Team for England and Wales. The national heart failure audit for England and Wales 2008-2009. Heart 2011;97:876-86.
2. National Heart Failure Audit. Report for 2009/10. http://www.ic.nhs.uk/ webfiles/ Services/NCASP/audits%20and%20reports/NHS-National-Heart-Failure- Audit-09-INTERACTIVE.pdf (accessed Jul 2011).
3. Wong CY, Chaudhry SI, Desai MM, et al. Trends in comorbidity, disability and polypharmacy in heart failure. Am J Med 2011;124:136-43.
4. Gurwitz JH, Goldberg RJ. Age-based exclusions from cardiovascular clinical trials: implications for elderly individuals (and for all of us): comment on "the persistent exclusion of older patients from ongoing clinical trials regarding heart failure". Arch Intern Med 2011;171:557-8.
5. National Institute for Clinical Excellence. Chronic Heart Failure. Clinical Guidleine 108. London UK: National Institute for Clinical Excellence, 2010.
6. Al-Mohammad A, Mant J. The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. Heart 2011;97:411-16.
7. Joynt KE, Orav EJ, Jha AK. The association between hospital volume and processes, outcomes and costs of care for congestive heart failure. Ann Intern Med 2011;154:94-102.
8. Macgowan GA, Parry G, Schueler S, et al. The decline in heart transplantation in the UK. BMJ 2011;342:d2483.
9. Banner NR, Bonser RS, Clark AL, et al. Guidelines for referral and assessment of adults for heart transplantation. Heart 2011;97:1520-7.
10. Riezebos RK, Ronner E, Ter Bals E, et al; OPTIMA trial. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. Heart 2009;95:807-12.
11. Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev 2010;(8):CD007228.
12. Chaudhry SI, Mattera JA, Curtis JP, et al. Telemonitoring in patients with heart failure. N Engl J Med 2010;363:2301-9.
13. Koehler F, Winkler S, Schieber M, et al; Telemedical Interventional Monitoring in Heart Failure Investigators. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation 2011;123:1873-80.
14. Bourge RC, Abraham WT, Adamson PB, et al; COMPASS-HF Study Group. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol 2008;51:1073-9. (Pubitemid 351374766)
15. Hoppe UC, vanderheyden M, Sievert H, et al. Chronic monitoring of pulmonary artery pressure in patients with severe heart failure: multicentre experience of the monitoring Pulmonary Artery Pressure by Implantable device Responding to Ultrasonic Signal (PAPIRUS) II study. Heart 2009;95:1091-7.
16. Abraham WT, Adamson PB, Bourge RC, et al; CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011;377:658-66.
17. Ritzema J, Troughton R, Melton I, et al; Hemodynamically Guided Home Self- Therapy in Severe Heart Failure Patients (HOMEOSTASIS) Study Group. Physiciandirected patient self-management of left atrial pressure in advanced chronic heart failure. Circulation 2010;121:1086-95.
18. Felker GM, Hasselblad V, Hernandez AF, et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009;158:422-30.
19. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009;55:53-60.
20. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9. (Pubitemid 44079340)
21. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-9. (Pubitemid 44088349)
22. Burkhoff D, Maurer MS, Packer M. Heart failure with a normal ejection fraction: is it really a disorder of diastolic function? Circulation 2003;107:656-8. (Pubitemid 36222586)
23. Brutsaert DL, De Keulenaer GW. Diastolic heart failure: a myth. Curr Opin Cardiol 2006;21:240-8. (Pubitemid 44315090)
24. Borlaug BA, Jaber WA, Ommen SR, et al. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 2011;97:964-9.
25. Holland DJ, Prasad SB, Marwick TH. Contribution of exercise echocardiography to the diagnosis of heart failure with preserved ejection fraction (HFpEF). Heart 2010;96:1024-8.
26. Tan YT, Wenzelburger F, Lee E, et al. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist and longitudinal motion. J Am Coll Cardiol 2009;54:36-46.
27. Tan YT, Wenzelburger F, Lee E, et al. Reduced left atrial function on exercise in patients with heart failure and normal ejection fraction. Heart 2010;96:1017-23.
28. Zile MR, Gaasch WH, Anand IS, et al; I-Preserve Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010;121:1393-405.
29. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-8.
30. Konstam MA, Neaton JD, Dickstein K, et al HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840-8.
31. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
32. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. (Pubitemid 36384098)
33. Zannad F, McMurray JJ, Krum H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
34. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51. (Pubitemid 39025171)
35. Pitt B, Anker SD, Bushinsky DA, et al; PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011;32:820-8.
36. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol 1997;30:1104-6. (Pubitemid 27435908)
37. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-9F. (Pubitemid 16054097)
38. Swedberg K, Komajda M, Böhm M, et al; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85.
39. Böhm M, Swedberg K, Komajda M, et al SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886-94.
40. Cullington D, Goode KM, Cleland JGF, et al. Rate criteria provide limited application for ivabradine in chronic heart failure Heart (2011). doi:10.1136/heartjnl-2011-300041.
41. Witte KK, Desilva R, Chattopadhyay S, et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 2004;147:924-30. (Pubitemid 38881010)
42. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103-12.
43. Anker SD, Comin Colet J, Filippatos G, et al; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
44. van der Meer P, Groenveld HF, Januzzi JL Jr, et al. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009;95:1309-14.
45. Beadle RM, Frenneaux M. Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease. Heart 2010;96:824-30.
46. Lee L, Campbell R, Scheuermann-Freestone M, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112:3280-8. (Pubitemid 43739373)
47. Fragasso G, Salerno A, Lattuada G, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart 2011;97:1495-1500.
48. Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011;97:278-86.
49. Cleland JG, Daubert JC, Erdmann E, et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49. (Pubitemid 40517094)
50. Cleland JG, Calvert MJ, Verboven Y, et al. Effects of cardiac resynchronization therapy on long-term quality of life: an analysis from the CArdiac Resynchronisation- Heart Failure (CARE-HF) study. Am Heart J 2009;157:457-66.
51. Cleland JG, Freemantle N, Daubert JC, et al. Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study. Heart 2008;94:278-83. (Pubitemid 351303415)
52. Moss AJ, Hall WJ, Cannom DS, et al; MADIT-CRT Trial Investigators. Cardiacresynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-38.
53. Tang AS, Wells GA, Talajic M, et al; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-tomoderate heart failure. N Engl J Med 2010;363:2385-95.
54. Chung ES, Leon AR, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation 2008;117:2608-16.
55. van Bommel RJ, Gorcsan J 3rd, Chung ES, et al. Effects of cardiac resynchronisation therapy in patients with heart failure having a narrow QRS Complex enrolled in PROSPECT. Heart 2010;96:1107-13.
56. Foley PW, Patel K, Irwin N, et al. Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration: the RESPOND study. Heart 2011;97:1041-7.
57. Sipahi I, Carrigan TP, Rowland DY, et al. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy. Meta-analysis of randomized controlled trials. Arch Intern Med. Published Online First: 20 June 2011. doi:10.1001/ archinternmed.2011.247.
58. Lavalle C, Ricci RP, Santini M. Atrial tachyarrhythmias and cardiac resynchronisation therapy: clinical and therapeutic implications. Heart 2010;96:1174-8.
59. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010;31:2677-87.
60. Shelton RJ, Clark AL, Goode K, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009;95:924-30.
61. Yu CM, Chan JY, Zhang Q, et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 2009;361:2123-34.
62. Conraads VM, Beckers PJ. Exercise training in heart failure: practical guidance. Heart 2010;96:2025-31.
63. Rees K, Taylor RS, Singh S, et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev 2004;(3):CD003331.
64. O'Connor CM, Whellan DJ, Lee KL, et al HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439-50.
65. Flynn KE, Piña IL, Whellan DJ, et al HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1451-9.
66. Spruit MA, Eterman RM, Hellwig VA, et al. Effects of moderate-to-high intensity resistance training in patients with chronic heart failure. Heart 2009;95:1399-408.
67. Kjekshus J, Apetrei E, Barrios V, et al CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61. (Pubitemid 350190755)
68. Rizzello V, Poldermans D, Biagini E, et al. Prognosis of patients with ischaemic cardiomyopathy after coronary revascularisation: relation to viability and improvement in left ventricular ejection fraction. Heart 2009;95:1273-7.
69. Cleland JG, Calvert M, Freemantle N, et al; The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail 2011;13:227-33.
70. Velazquez EJ, Lee KL, Deja MA, et al; for the STICH Investigators. Coronary artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364:1607-16.
71. Cleland JG, Freemantle N. Revascularization for patients with heart failure. Inconsistencies between theory and practice. Eur J Heart Fail 2011;13:694-7.
72. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.
73. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
74. Massie BM, O'Connor CM, Metra M, et al; PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-28.
75. Voors AA, Dittrich HC, Massie BM, et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol 2011;57:1899-907.
76. Felker GM, Lee KL, Bull DA, et al; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797-805.